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ABSTRACT 
Rachel Henderson; Telomere Maintenance as a Therapeutic Target 
(Under the direction of Michael Jarstfer) 
 
 
Telomere maintenance is essential for long term cell survival, with two mechanisms 
contributing to telomere maintenance: telomeric DNA elongation by telomerase and a capping 
mechanism contributing to telomere stability. Several therapeutic approaches targeting telomeres 
have been explored but many rely on a lag period of telomere degradation before anti-
proliferation occurs. Two strategies presented here aim to disrupt telomere maintenance while 
eliminating the lag period. First, telomerase was inhibited using antisense oligonucleotides 
targeting its RNA subunit (hTR). The goal of this study was to both prevent active holoenzyme 
assembly and induce degradation of the protein subunit (hTERT) thought to be associated with 
anti-apoptotic activity. Additionally, a fluorescence polarization assay was designed for the 
identification of small molecule inhibitors of telomeric repeat binding factor 2 (TRF2), a key 
capping protein involved in prevention of chromosomal end fusions and ultimately cellular 
apoptosis. 
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CHAPTER 1: INTRODUCTION 
 
I. Overview of Telomeres, Telomerase, and Cancer 
Since its discovery, deoxyribonucleic acid (DNA) has been considered the primary 
carrier of the ‘blue print’ of life utilizing four nucleotide bases in an alpha helix.  With the 
average length of a single DNA strand being ~6 feet, high orders of structure and unique 
mechanisms are required to both effectively package the DNA into the nucleus of a single cell 
and to ensure that genetic data is protected and maintained. This abundance of DNA is tightly 
coiled around histone proteins into structures called chromosomes. The ends of eukaryotic 
chromosomes are capped with tandem, G-rich TTAGGG DNA sequences called telomeres. 
Repeating telomeric sequences are oriented 5’ to 3’ towards the end of the chromosome leading 
to a single stranded 3’ overhang (Figure 1.1).1 Telomeres provide stability and protection from 
DNA degradation and chromosomal end fusions to prevent the loss of essential genes and ensure 
information stored in DNA is properly replicated during mitosis.
2,3
  
Maintenance of telomere ends is essential for long term survival. The enzyme responsible 
for maintaining telomeric DNA is telomerase, a specialized RNA-dependent DNA polymerase. 
Telomerase functions to lengthen telomeres protecting them from erosion. It is clear that 
telomerase activity is important for the survival of the cell and protection of its genetic data. 
However, catalytic telomerase is not expressed in differentiated human cells. Interestingly, it is 
found almost ubiquitously in cancer cells, nearly 90% are telomerase positive, making the 
enzyme an important player in cancer biology.  
2 
 
  
 
 
Cancer remains one of the leading causes of death in the U.S. Because telomerase is 
active in the majority of cancer cells, it is an almost universal marker for human cancer.
2,3 
While 
standard chemotherapeutic regimens are often associated with toxic side effects, telomerase is a 
therapeutic target that provides a means of reducing toxicity to healthy cells due to its specificity 
to tumor cells.
4
 
 
II. Telomere Replication and Telomerase Function 
During telomere replication, DNA polymerase duplicates template strands of DNA from 
the origin of replication to the chromosome termini. The leading strand is continuously replicated 
in the 5’ to 3’ direction to the end of the template. In comparison, the lagging strand requires a  
Figure 1.1 DNA Packaging. Telomeric DNA caps the ends of 
chromosomes that are wound into histones and packaged into 
the cell nucleus. Adapted from www.genome.gov/DIR/VIP/ 
Learning_Tools/genetic_illustrations.html. 
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backstitching mechanism leaving a gap in the lagging strand DNA copy in what is known as “the 
end replication problem” (Figure 1.2). This mechanism involves the introduction of RNA 
primers at regular intervals. DNA polymerase extends these primers to synthesize DNA 
fragments termed Okazaki fragments that make up the lagging strand. The primers are eventually 
removed and the gaps left behind are filled in with DNA and the fragments are ligated together. 
However, when the last RNA primer is removed DNA polymerase cannot bind to fill in this gap, 
leaving a shortened lagging strand. If not corrected, chromosomes shorten with each successive 
replication cycle. Telomerase is the human enzyme that counteracts this end replication problem. 
Telomerase is a multiunit complex consisting minimally of two essential components, a 451 
nucleotide long RNA subunit (hTR) and a protein subunit (hTERT). hTR contains several 
functional domains and a templating sequence serving as a template for synthesis of telomeric 
repeats while hTERT is a reverse transcriptase. Although hTERT is repressed during 
differentiation, hTR is expressed constitutively. Telomerase stabilizes telomere length by adding 
telomeric repeat (TTAGGG)n to the 3’ end of chromosomes. To accomplish this, the RNA 
Figure 1.2 The End Replication Problem. Inefficient 
DNA synthesis results in a shortened lagging strand and a 
3’ overhang. Adapted from http://www.senescence.info/ 
telomeres_telomerase.html 
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subunit hybridizes to the 3’ overhang and the catalytic subunit repetitively reverse transcribes the 
template region of the RNA moiety. DNA polymerase then fills in the region on the opposite 
strand (Figure 1.3).
5
   
 
 
 
 
III. Implications of Telomere Shortening 
 In the absence of telomerase, linear chromosomes progressively shorten in proliferative 
cells, resulting in a finite number of possible cell divisions.
6
 Once the telomeres in a cell reach a 
critically short length, division ceases and cells enter replicative senescence or mortality stage 
(M1).
7
 Occasionally, cells bypass senescence due to mutations in the p53 tumor suppressor 
protein. p53 is an essential cell-cycle checkpoint protein that serves to halt cell cycle progression 
Figure 1.3 Telomerase-Mediated Telomere Extension. Telomerase, a RNA-
dependent DNA polymerase, extends the 3’ overhang. DNA polymerase fills in the 
opposite strand. Adapted from THE CELL, Fourth Edition, 2006. 
5 
 
and has an important role in the initiation and maintenance of the senescence state. Cancer 
progression involves both the enhancement of cell growth factors and the repression of cancer 
suppressors, therefore it is not surprising that when wild type p53 was introduced into SiHa cells 
it was shown to negatively regulate hTERT mRNA expression.
8
 Cells with mutated p53 continue 
to divide despite short telomeres until they reach a crisis stage (M2) in which massive cell death 
occurs. In rare occasions cells are able to escape crisis by up regulating the catalytic hTERT 
subunit and activating telomerase, thus leading to immortal cancer cells (Figure 1.4 and 1.5).
1,9,10
 
As mentioned previously, telomerase is expressed in the majority of cancers, however in the 
remaining 10% of telomerase negative tumor cancer cells, an alternative recombination 
mechanism is employed to maintain telomere length, suggesting the importance of telomere 
maintenance in cell survival and immortality. 
  
Figure 1.4 Mechanism of Cellular Immortalization. Cellular senescence 
occurs after  telomere shortening which can lead to the crisis stage. In rare 
events cells escape crisis and become immortal. Adapted from Shay and Wright, 
Nat Rev Drug Discov. 2006. 
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Cancer cells undergo robust proliferation, and telomere maintenance provided by 
telomerase is key for their survival. Tumor cells tend to have shorter telomeres than healthy cells 
but show no net loss of average telomere length with each successive cell division, again 
implying telomere stability is needed for continuous proliferation.
2
 Because it is up-regulated in 
tumor cells and is essential for the survival of many cancer cells, telomerase has been explored 
as an anticancer drug target.  Inhibition of telomerase activity results in a gradual loss of 
telomere length, thus causing cancer cells to enter into a crisis stage leading to senescence and/or 
cell death. 
 
 
 
 
 
Figure 1.5 Cellular Senescence Induced by Telomere Shortening. In the absence 
of telomerase, telomere length decreases with increased cell divisions. Cancer cells 
tend to have shorter telomeres than healthy cells but show no net loss of telomere 
length. Adapted from Hayflick, Exp. Cell Res.1965.  
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IV. Telomere Capping 
Telomere DNA maintenance is important because short telomeres cannot form the proper 
protective cap. In addition to targeting cancer cells via telomerase inhibition, one could envision 
targeting the DNA binding proteins involved in telomere capping. These proteins contribute to 
the stabilization and maturation of the telomerase shelterin complex. The shelterin complex is 
composed of several telomere specific proteins including POT1, TIN2, TPP1, Rap1, and 
homodimers of TRF1 and TRF2 that bind single and double stranded telomere regions to form a 
complex that caps the ends of chromosomes. Shelterin functions to protect telomeres by 
establishing the structure of the telomere terminus and controlling synthesis of telomeric DNA 
by telomerase. In part, protection appears related to the generation of a telomeric loop structure 
known as a t-loop (Figure 1.6).
3,12
  T-loops are formed when the single stranded 3’ overhang 
tucks into the duplex part of the  telomeric repeat array protecting telomeres from degradation,  
Figure 1.6 Shelterin Complex and T-loop Formation. The shelterin complex binds 
telomere regions to induce a t-loop formation capping the ends of chromosomes. 
Adapted from Huzen et al, Frontiers in Bioscience, 2010. 
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recombination, and end-joining reactions.
2,13
 Additionally, it is important to note that shelterin 
associated proteins are essential in assemblage of additional protein components involved in the 
formation of a higher order nucleoprotein complex present at telomeres.
1,11
 
Telomeres can be considered as either capped or uncapped. Capped telomeres are 
telomerase inaccessible and allow cell division to proceed. However, telomere shortening 
increases the probability of telomeres switching to their uncapped state where elongation by 
telomerase can occur. Consequently, the shortest telomeres are preferentially targeted for 
elongation allowing maintenance of a steady-state telomere length.
14
 The uncapped state can lead 
to irreversible cell cycle arrest and death depending on the functionality of the 
telomere/telomerase complex including the loss of active telomerase and prevention of t-loop 
formation.
11
 If left uncapped, the telomere is recognized as DNA damage and the cell cycle 
arrests. Cell machinery works to remove the damage signal by fixing DNA breaks through end-
to-end fusion of telomeres, leading to telomere instability upon resuming cell division (Figure 
1.7).
6
 These defective chromosomes break during mitosis again activating damage signaling.
15
 
However, it is evident that functional telomeres are capable of avoiding the DNA damage 
response as the telomeric complex grants cells the ability to distinguish chromosome ends from 
random DNA breaks.
6,13,16
 It has been shown that telomere repeat binding factor 2 (TRF2) may 
play a major role in the protection of human chromosome ends by preventing the damage 
response. TRF2 coats human telomeres during all stages of the cell cycle by binding directly to 
the tandem TTAGGG repeats.
13
 In vitro data indicates that the addition of TRF2 protein to a 
linear DNA telomeric model promotes t-loop formation.
16
 Furthermore, inhibition of TRF2 and 
POT1, a similar single stranded telomeric DNA binding protein, by dominant negative alleles 
leads to immediate activation of the ATM/p53-dependent DNA damage pathway causing cell  
9 
 
 
 
 
apoptosis in many cell types as well as a substantial fraction of fusing between telomeres. 
Similar results were seen in TRF2 knock out mouse models.
17
 This is consistent with the model 
that TRF2 depleted telomeres are perceived as sites of DNA damage. It is thought that telomere 
dysfunction may be caused by the loss of the 3’ overhang leading to the failure to reform the t-
loop.
13,16
  From these observations it is clear that targeting TRF2 would be an appealing 
approach for drug discovery. However, it is possible this mechanism may be associated with 
reduced specificity because proper telomere formation is required in all healthy somatic cells. 
Studies using a mouse model suggest that telomere disrupters are highly tolerated in normal cells 
for finite periods of time. Like TRF2, POT1 is essential for telomere protection. In one study a 
ligand stabilized version of POT1 allowed POT1 to be inhibited transiently and reversibly. 
Remarkably, POT1 inhibition resulted in cancer cell death, but normal cells underwent arrest that 
Figure 1.7 Telomere Capping Two State Model. Telomeres 
switch between a capped and uncapped state in response to 
telomere length and telomerase status. Adapted from Blackburn, 
Science, 2000. 
10 
 
was reversed by POT1 reactivation.
18 
This suggests that small molecule inhibition of telomere 
binding proteins may provide a high therapeutic index as anti-cancer agents.  
 
 
V. Research Projects 
Several strategies to target telomere maintenance have been explored. These include the 
use of antisense oligonucleotides and hammerhead ribozymes to target the mRNA of hTERT, 
immunotherapies, and gene therapy approaches.
19
 Although complex in their modes of action 
these methods are associated with immediate anti-proliferative effects. Alternatively, there are 
antisense oligonucleotides targeting the hTR template region, small molecules telomerase 
inhibitors, and G-quadraplex stabilizers.
9,15,19
 These therapies directly interfere with telomerase 
enzymatic function, relying on a lag period of telomeric erosion before proliferative effects 
occur. As a whole these strategies encompass a broad area of research, differing considerably in 
their anti-cancer mechanisms. We will first focus on the latter group whose therapeutic effects 
are controlled by a lag period, and then introduce the two approaches presented in this thesis 
aiming to eliminate the lag period. 
Much progress has been made with telomerase based therapeutics, but as with any 
telomerase inhibitor it may require several cell divisions before proliferation effects becomes 
apparent. The initial lengths of telomeric DNA in cancer cells are hundreds or thousands of base 
pairs long. In the absence of telomerase, proliferating cells lose only 50-200 base pairs of 
telomeric DNA with each cell cycle. Once telomerase is inhibited, telomere length progressively 
shortens until cellular senescence is attained. As shown in Figure 1.8, traditional anti-
proliferative agents have an immediate inhibitory effect on cell growth whereas a telomerase 
11 
 
inhibitor’s is delayed. Not only does this lag period depend on telomere length but also rate of 
erosion.
20,21
 One study using oligonucleotides complementary to the hTR template region 
showed once telomerase activity was inhibited cell lines did not display anti-proliferative effects 
until thirty days after treatment.
22
  
 
 
 
It is accepted that hTR is highly expressed in all normal tissue whereas hTERT is present 
only in immortal cells. Tumor growth requires reactivation of hTERT and its introduction into 
telomerase silent cells is sufficient to reactivate telomerase leading to cell immortalization.
2,9,22
 
For example when oligonucleotides are used to inhibit telomerase, upon discontinuing 
oligonucleotide treatment telomerase is reactivated and telomeres return to their initial length.  
Figure 1.8 Therapeutic Lag Period. Telomerase inhibitors rely on telomere 
erosion resulting in an anti-proliferative lag period. Adapted from Corey, 
Oncogene, 2002. 
12 
 
Therefore, one challenge in designing telomerase targeted treatment strategies is the need to 
continuously treat patients during multiple tumor cell population doublings.
15
 A valuable 
alternative strategy would be to evade telomerase reactivation by hTERT. Using antisense 
oligonucleotides as a therapeutic approach, hTR was selected as the target for my first project 
based on our hypothesis that a misassembled holoenzyme may lead to the degradation of hTERT 
possibly allowing treatment without continuous dosing. Furthermore, it is widely known that the 
classical role of telomerase is to elongate telomeric DNA, but there is emerging evidence that 
hTERT is involved in other functions including apoptotic activity.
21
 Previous studies 
demonstrated that overexpression of hTERT renders cells more resistant to apoptosis.
23 
Likewise, 
there have been several studies showing that inhibiting hTERT expression can cause an 
immediate apoptotic response.
24,25,26
 One study using modified antisense oligonucleotides to 
target both hTERT and hTR mRNA in DU145 human prostate cancer cells found that while both 
targets caused complete inhibition of telomerase activity, hTERT down regulation showed an 
early decline in cell growth and an induction of apoptotic cell death, whereas hTR down 
regulation failed to interfere with cell proliferation prior to telomeric DNA erosion.
27
 
Additionally, studies using cell culture and a transgenic mouse model show that hTERT 
promotes cellular and organismal survival independent of telomerase activity.
28
 Expression level 
of hTERT positively correlated with cell survival after exposure to several lethal stresses, 
whereas expression level of hTR had no effect on sensitivity.
27
 The mechanism behind hTERT 
induced apoptosis is unclear, however these results are significant because not only would we 
like to use antisense oligonucleotides to achieve hTERT degradation and prevent telomerase 
function and reactivation, but also consequently induce apoptosis of cancer cells to eliminate the 
lag period. However, while these studies target hTR and hTERT mRNA, we are interested in 
13 
 
hybridizing oligonucleotides to the hTR structural subunit. This strategy can be used to examine 
what happens when telomerase assemblage is disrupted and may serve as a model for the 
development of future therapeutics, for example small molecule telomerase inhibitors. 
Direct telomerase inhibition through oligonucleotide hybridization is a multifaceted 
therapeutic approach with many considerations. Nonetheless it has shown to be promising as an 
anticancer strategy. GRN163L is a lipid-conjugated N3′→P5′ thio-phosphoramidate 
oligonucleotide that blocks the template region of telomerase. Various studies have demonstrated 
that GRN163L treatment leads to significantly reduced telomerase activity, promoting telomere 
loss and apoptosis in several cancer lines.
29,30
 The high potency and specificity of GRN163L as 
well as modifications to improve its bioavailability has led to its testing in ongoing clinical trials. 
Although not effective within hours or days as most primary anti-proliferative cancer therapies, 
telomerase inhibition may weaken cells making them more susceptible to other anti-proliferative 
agents, suggesting that use in combination treatments may be an effective route.
4,20
 Again, we 
would like to discover a novel approach, eliminating the lag period and need for combination 
therapy, and instead offer telomerase inhibition as a primary anti-cancer treatment.  
In addition to telomerase inhibition induced by oligonucleotide hybridization, disruption 
of telomere maintenance can be achieved through the targeting of DNA binding proteins 
involved in the regulation of telomeres. As mentioned previously, TRF2 is critical to the 
protection of telomeric DNA through its function in telomere capping and elimination of DNA 
damage signals. Impaired telomere capping leads to cell cycle arrest, meaning that by disrupting 
the function of TRF2 cellular senescence can be obtained without relying on telomere 
shortening. This is another approach that eliminates the delay in anti-proliferative effects that is 
seen with existing telomerase inhibiting therapeutics. 
14 
 
Current treatments targeting telomerase activity exhibit a lag period and will have to be 
used in combination therapies. As an alternative approach to remove the lag period, my thesis 
research involves inducing the dysfunction of telomeres, specifically examining how both 
telomere length and telomere capping status contributes to telomere function. The first part of 
my project involves oligonucleotide based inhibition of telomerase activity using a novel 
approach to inhibit telomerase that may block noncanonical hTERT activity and induce 
apoptosis. My second project involves the disruption of the essential capping protein TRF2 using 
small molecule inhibitors to test the hypothesis that the uncapping of telomeres leads to rapid 
induction of cell growth arrest.
1,2
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CHAPTER 2: TELOMERASE INHIBITION THROUGH OLIGONUCLEOTIDE 
TRANSFECTION 
 
 
I. Introduction 
Transfection, the process of introducing nucleic acids into mammalian cells, is commonly 
used in drug discovery to study the effects of a modified biological activity. In this project, 
oligonucleotides were introduced into PC-3 cancer cells to investigate the inhibition of 
telomerase by disrupting specific protein-RNA interactions. Oligonucleotides are short, single 
stranded modified DNA or RNA molecules that can be designed to be complementary to a 
specific target allowing for hybridization and inhibition of a desired biological function. 
Antisense oligonucleotides are generally used to prevent protein translation by targeting mRNA. 
In this project, a RNA antisense oligonucleotide with modified bases was used to inhibit 
telomerase, specifically through hybridization with the structural hTR subunit to sterically 
prevent proper holoenzyme association with hTERT. A major challenge in this therapeutic 
approach is getting oligonucleotides into the cell and to telomerase without being degraded.
2
 
Fortunately, cationic lipid transporters can be used to facilitate uptake. Cationic lipids are 
positively charged having the ability to interact with negatively charged DNA and cell 
membranes. Lipid and oligonucleotides spontaneously complex during an incubation period and 
then fuse the cell membrane to deposit the oligonucleotide inside the cell.
31
 There are several 
advantages to using oligonucleotides for hTR targeting. For one, the necessity of hTR for 
telomere binding and its accessibility by oligonucleotides makes it an ideal target. Additionally, 
16 
 
oligonucleotides are commercially available and because they are complementary to the known 
hTR sequence they are both highly specific and easily designed.
20 
 
In standard studies, to conclude that oligonucleotides are inhibiting telomerase through 
complementary binding rather than off target effects, one must consider the following; due to the 
lag period, inhibitors should reduce telomerase activity but should not affect cell growth rates 
initially.  Hence, cells should eventually undergo growth arrest and apoptosis but again this time 
is dependent on initial telomere length.
22
 However with our approach, holoenzyme misassembly 
and hTERT degradation could lead to immediate cellular consequences by interruption of an 
anti-apoptotic pathway. 
 
II. P6.1 Loop Target and hTRas012 Development 
The specific target sequence I focused on was the P6.1 loop of telomerase hTR, a RNA 
sequence critical for telomerase subunit assembly (Figure 2.1A).
32
 By targeting hTR/hTERT 
binding, proper assemblage of the active holoenzyme complex is prevented causing inhibition of 
enzyme function. As mentioned previously a misassembled holoenzyme may lead to the 
degradation of hTERT. This is significant because this subunit correlates to activation of 
telomerase dependent telomere lengthening and cancer cell progression. It is also important to 
note that although hTR is highly expressed in normal tissue, there is no evidence that it has any 
function outside of telomerase.
33,34
 Therefore this target is selective toward telomerase activity 
and cancer progression specific to tumor cells. 
 
17 
 
 
 
 
 
Previous work in our laboratory showed that targeting certain hTR regions using 
antisense oligonucleotides results in decreased telomerase activity(Table 2.1).
35
 To determine 
inhibitory effects on the enzyme, a telomerase assemblage assay was employed in which hTR 
and hTERT were assembled in reticulocyte lysates. Telomerase activity was measured using a 
direct telomerase assay. In the regions targeted, the greatest inhibitory effect was observed in the 
pseudoknot (P3/P1) and CR4-CR5 (P6.1) domains demonstrating that these areas are essential 
for telomerase activity and subunit binding. Accordingly, both of these regions are conserved in 
vertebrate telomerase RNAs, and neither are exposed after holoenzyme assembly.
36
  In a 
telomerase assemblage assay oligonucleotides hTRas009 and hTRas010 targeting the P3/P1 
Figure 2.1 hTR RNA Subunit Structure and hTR P6.1 Loop. A. The 451 nucleotide long hTR 
subunit structure. B. The P6.1 loop within the CR4/CR5 domain. Highlighted nucleotides represent the 
hTRas012 target. Adapted from Legassie et al. Structure, 2006. 
18 
 
pairing region and the P6.1 loop within the CR4-CR5 domain respectively, inhibited telomerase 
with IC50s in the nanomolar range . Co-immunoprecipitation assays confirmed the 
oligonucleotides ability to prevent binding of targeted hTR regions to hTERT. However no 
significant inhibition was seen when added to preassembled telomerase in a direct telomerase  
 
 
 
 
assay. Furthermore, full length hTR still had the ability to bind hTERT in the presence of 
oligonucleotides suggesting binding of hTRas009 and hTRas010 prevents proper holoenzyme 
assembly and sequesters telomerase subunits in an inactive state. Preference for which 
oligonucleotide to further examine was influenced by the observation that hTRas010 showed a 
greater ability to prevent binding between its targeted region and hTERT than hTRas009 (~92% 
compared to ~50%). In accordance with these results previous studies had demonstrated that the 
presence of the P6.1 loop was necessary for interaction between the CR4-CR5 region and 
hTERT as well as enzymatic activity of the mammalian telomerase complex.
32
 Based on this 
Name Sequence hTR region targeted 
nucleotide 
targeted 
% 
activity 
hTRas001 5'-ATGGCAAGTCCGAATCGATCGT-3' none N/A 804 
hTRas002 5'-TAGGGTTAGACAA-3' template (CR1) 42-54 97 
hTRas003 5'-AAAGTCAGCGAGAAAAACAGCG-3' 
pseudoknot domain 
(CR2/CR3) 94-115 97 
hTRas004 5'-AACGGGCCAGCAGCTGACATTT-3' P3/P1 pairing region 174-195 37 
hTRas005 5'-TGGGTGCCTCCGGAGAAGCCCC-3' L6 loop 268-289 100 
hTRas006 5'-CGGCTGACAGAGCCCAACTCTT-3' CR4-CR5 domain 301-322 54 
hTRas007 5'-GCCTGAAAGGCCTGAACCTCGC-3' 
hypervariable paired 
region 343-364 115 
hTRas008 5'-ACAGCTCAGGGAATCGCGCCGC-3' CR7 domain 397-418 74 
hTRas009 5'-AACGGGCCAGCAGCUGACAUUU-3' P3/P1 pairing region 174-195 12 
hTRas0010 5'-CGGCUGACAGAGCCCAACUCUU-3' CR4-CR5 domain 301-322 18 
Table 2.1 Summary of Inhibition Data with hTR-Targeted Oligonucleotides. DNA oligonucleotides were 
added to hTERT and hTR prior to assemblage. Telomerase activity was determined using a direct telomerase 
assay. “% Activity” indicates the amount of residual telomerase activity at a 1 uM concentration compared to 
the primer-only control. hTRas009 and hTRas010 are 2-O-methyl oligonucleotides, and underlined 
nucleotides indicate phosphorothioate linkages. 
19 
 
consideration, oligonucleotide hTRas012 was designed by lab members with the capability of 
interacting with the P6.1 stem loop, specifically targeting nucleotides 298-310 (Figure 2.1B). 
The hTRas012 sequence is 5’- CCCAACTCTTCGC-3’ with all RNA bases 2’-O-methyl 
modified and underlined bases indicating phosphorothioate linkages (Figure 2.2). Although DNA 
is the native substrate of telomerase, the 2’-O methyl RNA modifications are used to increase 
binding affinity to prevent nonspecific interactions, while phosphorothioate linkages enhance 
stability against nuclease digestion.
20
 Fully modified phosphorothioate linkages have been shown 
to have poor sequence selectivity possibly due to nonspecific protein interactions. Therefore, 2’- 
 
 
Figure 2.2 Oligonucleotide Backbone Modifications. 
Oligonucleotides have modified backbones to increase binding 
affinity and stability. 
20 
 
O- methyl modified RNA oligomers with terminal phosphorothioate linkages were selected to 
test this inhibition platform. These modifications also increase the serum half-life of the 
oligonucleotide, increasing its pharmacokinetic properties. Additionally, this design is both 
chemically and sterically similar to DNA allowing for favorable electrostatic contacts with the 
protein component of telomerase.
37
  
As expected hTRas012 showed complete telomerase inhibition with IC50 ranges in the 
low nM range when tested in a telomerase assemblage assay (~21 nM). Results from a 
scintillation proximity assay (SPA), performed to determine if the oligonucleotide prevented 
interaction between the protein and RNA subunits, showed that the addition of hTRas012 
prevented CR4-CR5/hTERT interaction in a concentration dependent manner yielding an IC50 
value of 96 nM. Because hTRas012 successfully inhibited telomerase in our previous studies it 
was chosen for further investigation in biochemical inhibition studies using cultured cells. 
Oligonucleotide transfection of hTRas012 was performed in PC-3 human cancer cells. A 
scrambled oligonucleotide with the sequence 5’-AGACUACUGAACU-3’ was used as a 
negative control for nonspecific effects. Again, both were 2’-O-methyl modified with underlined 
bases indicating phosphorothioate linkages. An Oligofectamine only negative control was also 
evaluated. Telomerase activity in treated cells was detected using the Telomeric Repeat 
Amplification Protocol (TRAP) assay. TRAP is a two-step PCR-based telomerase detection 
method (Figure 2.3). In the first step of the assay lysate telomerase adds telomeric repeats onto 
the 3’ end of substrate oligonucleotide (TS). This reaction mixture contains the reaction buffer 
provided with the kit, dNTPs, TS primer, and the desired cell lysate sample. In the second step, 
extended products are amplified by PCR using a primer mixture to produce a ladder of products 
that can later be visualized.
38
 In addition to the primer mix, this mixture contains dNTPs and Taq 
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polymerase. There are several control samples included in the assay. The positive control is a 
telomerase active pellet supplied in the kit. There are two negative controls including a lysis only 
sample to monitor contamination and a negative telomerase heat treated control corresponding to 
each lysate sample. Additionally, there is an internal control for each sample producing a 36 bp 
band in every lane to ensure no Taq polymerase inhibitors are present in the sample and to help 
monitor the amplification process. 
 
 
 
 
III. Materials and Methods 
PC-3 human cancer cells were obtained from UNC Lineberger Comprehensive Cancer 
Center. Cells were maintained in F-12K media with 10% FBS and a 1% concoction of penicillin, 
streptomycin, and amphomycin, and cultured at 37°C in a 5% CO2 incubator. Modified 
Figure 2.3 TRAPeze Assay Scheme. The two step TRAPeze assay used 
to assess telomerase activity in cell samples. Adapted from Millipore 
TRAPeze Telomerase Detection Kit Manual 
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oligonucleotides were purchased from Integrated DNA Technologies. For all transfections cells 
were seeded in 10% FBS, antibiotic free F-12K media in 12 well plates at 78,000 cells per well 
in order to obtain 40% confluence 24 hours after seeding. The transfection protocol supplied 
with the cationic lipid carrier Oligofectamine, provided by Invitrogen, was followed for all 
transfections. Twenty four hours after seeding, oligonucleotides were incubated with 
Oligofectamine in Opti-Mem media before adding to cells. Cells were washed and then 
transfected with oligonucleotides in serum free, antibiotic free F12-K media at a total volume of 
500 L for 4 hours before either adding 30% FBS, antibiotic free F12-K media to a final FBS 
concentration of 10% or alternatively removing transfection media and refreshing cells with 10% 
FBS, antibiotic free F12-K media. For longer transfections periods, when cells reached 100% 
confluence, populations were split to 40% confluence 2 hours prior to the next transfection. After 
the appropriate incubation period, cells were harvested by trypsinization and washed twice with 
PBS before spinning into pellets at 13,000 for 3 min at 4°C. Pellets were lysed using a CHAPS 
cell lysis buffer with added RNAase inhibitor at 200 units/mL. Lysate protein concentration was 
determined using a Bradford assay before separating lysates into 10 L aliquots and flash 
freezing for storage at -80°C. A TRAP assay was employed to assess telomerase activity. 
Components for TRAP were provided by the TRAPeze telomerase detection kits purchased from 
Millipore. A Master mix was prepared by mixing 1.25 L of 10X TRAP reaction buffer, 0.25 L 
50X dNTP, 50 ng/L TS primer, and 8.50 L PCR grade water per sample. Each sample 
required 10 L of Master mix and 3 L of lysate at a protein concentration of 200 ng/L. 
Samples were incubated at 30°C for 30 minutes and 95°C for 5 minutes. Next, 12 L of a PCR 
mix was added containing 0.50 L primer mix, 10.40 L PCR grade water, 1.25 L Taq buffer, 
0.25 L 50x dNTP, and 0.10 L Taq polymerase per sample. The final volume of each sample 
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was 25 L. Samples underwent 33 PCR cycles at 94°C for 30 seconds, 60°C for 30 seconds, and 
72°C for 1 minute. Both the Master mix and PCR mix as well as controls samples were prepared 
before preparing cell lysate samples. Here we used the gel based non-isotopic detection method 
with a 12.5% non-denaturing polyacrylamide gel (10% APS, 1% TEMED). TRAP dye 
composed of glycerol, 1.25% bromophenol blue, 1.25% xylene cyanol, and 0.05 M EDTA was 
added to PCR samples before gel loading and gels were run in 0.5X TBE buffer at 400 V for 45 
minutes. Gels were stained with SYBR Green DNA dye and visualized using a Storm scanner at 
450 nM. ImageQuant software was used to quantify the amount of telomeric product obtained 
from each cell sample lysate. Values were calculated by quantifying the amount of product in the 
non-heat treated sample (x), the corresponding heat treated sample (xo), the lysis buffer only 
control (c), and the internal standard (cr). Relative activity was calculated with the equation (x- 
xo / c) / (cr) and then graphed to compare the effects of different oligonucleotide concentrations.  
 
IV. Results 
To study the effect of inhibiting telomerase by blocking the interaction between P6.1 of 
hTR and hTERT, I determined conditions for transfecting PC-3 cells with hTRas012. It was 
expected that an increase in oligonucleotide concentration would reflect an increase in 
telomerase inhibition and less telomeric product. As mentioned previously, hTRas012 does not 
inhibit preassembled hTR-hTERT holoenzyme because the CR4-CR5 regions are not exposed 
after assemblage, meaning a telomerase turnover must occur before binding of the 
oligonucleotide to hTR. However, cancer cells are rapidly dividing and therefore rapidly 
transcribing hTR for the generation of more telomerase thus providing an opportunity for 
oligonucleotide hybridization. In order to determine a sufficient and optimal amount of time 
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needed to ensure binding, transfected cells were allowed to incubate for different time intervals 
before harvesting.  
In initial experiments cells were transfected with increasing oligonucleotide 
concentrations and incubated for 24 hours before harvesting and assessing telomerase activity. 
Four hours after transfection 30% FBS, antibiotic free F-12K media was added to transfection 
media to reach a serum concentration of 10%. When assessed for activity a concentration 
dependent inhibition of telomerase activity was observed (Figures 2.4 and 2.5). Repeating the 
transfection with increased concentrations (200 nm- 1 M) reflected similar results, however 
there was only about 45% inhibition associated with the maximum concentration of 1 M.  
In an attempt to completely inhibit telomerase activity, 48 hour single transfections and 
48 hour double transfections (2 transfections 24 hours apart) were performed with 
oligonucleotide concentrations ranging from 200 nM-1 M. When preparing for harvesting 48 
hours later the cells were clumped and floating including those transfected with the negative 
scrambled control. Transfection agents can cause toxicity to cells when introduced at too low of 
a cell confluency. To determine if toxicity was the problem, cell confluence was varied (30%, 
50%, 80%) before transfection while keeping the oligonucleotide concentration the same (200 
nM). Additionally, while keeping confluency at 40%, the oligonucleotide concentration was 
decreased (20-200 nM). After 24 hours all the cells were still alive, however cells were already 
completely confluent in all the wells except the initial 30% well. After 48 hours all the cells had 
died. It was concluded that the transfection conditions were toxic to the cells and media must be 
removed and refreshed after each 4 hour transfection period. Forty-eight hour transfections were 
repeated at 40% cell confluency and after 4 hours transfection media was removed and replaced 
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Figure 2.5 hTRas012 
Inhibition in 24 hr. 
Transfection. Telomerase 
activity based on 
quantification of telomeric 
product from the 
TRAPeze assay gel in 
Figure 2.4. 
Figure 2.4 TRAP 
Assay Gel for 24 hr. 
Transfection. A dose 
dependent telomerase 
inhibition is observed 
(20 nM-200nM). As  
hTRas012 
oligonucleotide 
concentration increases, 
telomeric product 
decreases. TSR8 serves 
as a PCR control. 
26 
 
with fresh 10% FBS, antibiotic free F-12k media. Cells survived but results showed inconsistent 
telomerase activity with no dose dependent inhibition. The experiment was repeated, but this 
time after 24 hours cells were split to achieve 40% confluence before the second transfection. 
Still adequate inhibition of telomerase activity was not observed in either the double or single 48 
hour transfections and additionally there was no dose dependent decrease in the 48 hour single 
transfection assay. However, the 48 hour double transfection did show a concentration dependent 
decrease in activity (Fig 2.6).   
 
 
 
 
 
Due to these results, a 72 hour (3 transfections 24 hours apart) incubation period of cells 
post initial transfection was attempted. Again, cells were split prior to each transfection to 
produce 40% confluence. After performing the TRAP assay on samples, results continued to be 
Figure 2.6 hTRas012 Inhibition in 48 hr. x 2 Transfection. 
Telomerase activity based on quantification of telomeric product from 
the TRAPeze assay gel in 48 hr. double transfections. A dose dependent 
telomerase inhibition is observed. 
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inconsistent, no dose dependent results were observed (Figure 2.7A). Transfections were 
repeated but this time without replacing media after the 4 hour transfection period and instead 
 
 
 
 
 
Figure 2.7 hTRas012 Inhibition in 72 hr. x 3 Transfection with and without 
Transfection Media Refresh. Telomerase activity based on quantification of 
telomeric product from the TRAPeze assay gel in 72 hr. triple transfections. A. 
Refreshed media after 4 hour transfection period. B. No refresh of transfection 
media after 4 hour transfection period. A dose dependent telomerase inhibition is 
observed. 
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adding 30% FBS to a total of 10% serum concentration as done in initial experiments. This time 
cells were split prior to each transfection and survived the 72 hour incubation period without 
toxicity. Moreover a dose dependent inhibition was observed with 45% inhibition of the negative 
control in the maximum dose (Figure 2.7B). Unfortunately, in all the experiments telomerase 
inhibition never reached more than about 40% of negative controls.  
 
V. Discussion 
Twenty four hour incubations consistently showed an hTRas012 dose dependent decrease 
in telomeric product, however complete inhibition of telomerase was never achieved. It is 
questionable whether discrepancies seen in longer than 24 hour experiments were due to 
complications arising from altered experimental conditions including longer incubation time 
intervals, cell splitting, and refreshment of transfection media after 4 hours. Despite the 
successful 48 hour double transfection, results from the 72 hour experiments suggest 
inconsistencies arouse from refreshing transfection media. Still these results are promising and 
suggest modifications to the current method may provide more satisfactory results. Additional 
studies may include testing higher concentrations of hTRas012 oligonucleotide or increasing 
transfection incubation times, however further optimization of transfection conditions is likely a 
beneficial approach to improving experimental results. There are several barriers to efficient 
transfection including the formation of oligonucleotide/cationic lipid complexes, entry of 
complexes into cells, oligonucleotide disassociation, and transport to the nucleus.
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Consequently, the ratio of cationic lipid reagent to DNA concentration is a key transfection 
parameter and special attention should be focused on determining ideal proportions. Although it 
does appear that oligonucleotides were entering the nucleus to bind hTR and inhibit telomerase, 
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a positive control is beneficial in optimizing transfection efficiency. There are several controls 
commercially available to help monitor whether oligonucleotides are entering the nucleus and to 
access toxicity of transfection conditions on cells. These methods commonly involve 
fluorescently tagged oligonucleotides and stains for cellular viability. 
Although efficient transfection is important to the success of oligonucleotide dependent 
telomerase inhibition, it is still possible a major drawback to this project involved inconsistencies 
associated with the TRAP assay. Results were difficult to reproduce and variable amongst 
duplicate experimental samples. Although one cannot rule out discrepancies in methodology, 
there are several limitations to TRAPeze involving factors affecting quantitative determination.
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It is a multi-step assay requiring several post PCR steps, thus allowing more opportunities for the 
introduction of error and contamination. In one study ten parallel TRAP reactions were 
performed using the TRAPeze kit and resulting telomeric product was quantified. A coefficient 
of variation from experiments was calculated to be 12%.
40
 Distributions with a coefficient of 
variation greater than one are considered to be of high variance, suggesting the TRAPeze assay is 
associated with high variability. Additionally the assay has a linear range of 250-5000 cells and 
is sensitive to sample concentration. The TRAP protocol suggests sample protein concentrations 
ranging from 10-750 ng/uL, but where within in this range is difficult to predict and once 
established for one experiment it may not produce optimal results for similar experiments run 
under the same conditions. Additionally, too low or too high protein concentrations can lead to 
PCR artifacts. Another common problem that existed throughout this project was negative 
controls containing telomerase positive cells resulted in low telomerase activity. However this 
data is questionable because as the protocol states, positive telomerase activity sometimes cannot 
be detected in concentrated extracts and must be diluted. For our experiments it was necessary to 
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maintain corresponding initial concentrations when comparing dose dependent samples. Finally, 
samples with inhibited telomerase may show an enhanced amount of telomerase activity because 
there are too many PCR cycles. In this case dramatically inhibited samples show telomeric 
product due to saturation of the PCR. 
Again, optimization of the current method may allow for improved results. Attention 
should first be focused on establishing optimal transfection conditions to improve transfection 
efficiency. Although TRAPeze is a widely used protocol for measuring telomerase activity, it 
may be beneficial to test samples using alternative quantification methods. For example, there 
are several modifications to the standard TRAP protocol including the incorporation of 
fluorescently labeled primers and real time PCR methods. There are also direct telomerase assays 
using radiolabeled dNTPs or primers that omit the PCR amplification steps, but these require 
large sample sizes to achieve enough telomerase activity.
41
  
Despite the challenges associated with this project, the dose dependent telomerase 
inhibition results are promising. Further efforts may uncover exciting knowledge contributing to 
progress in this novel area of anti-cancer therapy. 
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CHAPTER 3: A FLOURESCENCE POLARIZATION ASSAY TO IDENTIFY TRF2 
SMALL MOLECULE INHIBITORS 
 
 
I. Introduction 
In addition to telomerase inhibition, disruption of telomere maintenance can also be 
achieved through targeting of DNA binding proteins involved in the formation of the telomere 
shelterin complex. As discussed above, TRF2 is critical to the protection of telomeric DNA 
through its function in telomere capping and inhibition of DNA damage signals. Disrupting the 
function of TRF2 leads to cellular senescence or death without telomere shortening, eliminating 
the lag period that exists with telomerase inhibition. There is also promising evidence that 
targeting telomere binding proteins may be well tolerated by normal healthy cells. The goal of 
this project was to develop a high throughput screen to identify small molecule inhibitors of 
TRF2 by direct binding to the TRF2 protein.  
High throughput screening (HTS) is a method used in drug discovery for rapid 
identification of active compounds. It requires miniaturization and automation of bioassays to 
simultaneously test libraries of drug-like compounds. Typically assays are carried out on 
microplates and are assessed in a relatively short time period, however before large screenings 
can occur assays need to first be designed and optimized. Here we utilize fluorescence 
polarization (FP), a technique providing fast and accurate quantitative measurements, for the 
identification of TRF2 binding small molecules. Polarized light waves are characterized as 
vibrations that occur in a single plane. FP uses the general idea that polarization is a property of 
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light emitted from fluorescent molecules that can be characterized based on their fixed light 
excitation and emission properties. In this technique, a biological sample labelled with 
fluorophore is illuminated with linearly polarized u.v.-visible light at the wavelength of 
fluorophore absorption. The fluorophore absorbs a photon, briefly exciting it to a higher energy 
state before emitting it at a specific wavelength. The light photon emission passes through a 
rotatable linearly polarizing filter before detection (Figure 3.1). Instead of detecting the degree of 
polarization, change in fluorescence intensity is used to indirectly measure polarization. Change 
in fluorescence intensity is described by a ratio of two measurements, the emission intensity 
parallel and perpendicular to the plane of linearly polarized illumination light.
28
 The polarization 
value, being the ratio of the two fluorescence intensities, is a dimensionless number expressed in 
millipolarization units (mP).  
 
 
Figure 3.1 Basic Principle of Fluorescence Polarization. Light passes through a 
linearly polarizing filter to excite a fluorophore. The ratio of emission intensity 
measurements parallel and perpendicular to emission light are used to describe 
fluorescence polarization. Adapted from Lea and Simeonov, Expert Opin Drug 
Discov, 2011. 
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This concept is illustrated in Figure 3.2. Light has an electric field. When fluorophore 
adsorption vectors align parallel with the electric vector of linearly polarized excitation light they 
are selectively excited, whereas those perpendicular elude excitation. Small rapidly rotating 
molecules orient randomly during emission, resulting in low fluorescence. Larger, slowly 
rotating molecules align in the same plane as the excitation energy, resulting in higher 
fluorescence.
43,44
   
 
 
  
I attempted to optimize a homogenous FP assay to identify TRF2 inhibitors. In this assay 
Cy5 fluorescent dye was linked to double stranded telomeric DNA (TTAGGG)3 to observe its 
interaction with TRF2. Cy5 labeled DNA rotates quickly resulting in decreased polarization, but 
after incubation with TRF2 binding occurs resulting in a larger complex and slower rotation of 
the fluorescent dye, therefore increasing FP. The low and high fluorescence measurements were 
used as references for unbound TRF2 and full complex formation in experiments. The idea was 
that when a TRF2 binding small molecule was introduced, displacement of TRF2 from DNA or 
Figure 3.2 Physical Basis of Fluorescence Polarization. Larger rotating fluorophore 
vectors are more likely to align parallel with excitation light prior to emission to become 
selectively excited. Adapted from http://www.lifetechnologies.com/us/en/home/references 
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inhibition of DNA binding would result in rapidly rotating Cy5 fluorophores, decreasing 
fluorescence measurements. In theory these small molecules would be acting to inhibit TRF2 
function by preventing binding with DNA. Without telomeric DNA binding by TRF2, telomere 
capping cannot occur leading to telomere dysfunction. Using HTS we aimed to identify small 
molecules that lead to a decrease in FP of Cy5 using an automated plate reader. In preliminary 
assay experiments we used an excess of unlabeled telomeric double stranded DNA (dsDNA) to 
behave as a TRF2 binding small molecule by displacing TRF2 from Cy5 labelled DNA.  
 
II. Materials and Methods 
Active TRF2 protein was obtained from Brian Bower of the Griffith laboratory at UNC- 
Lineberger Cancer Center. The protein was provided in 15 g/ 25 L aliquots at a concentration 
of 9.97 M. The TRF2 oligonucleotides (TTAGGGTTAGGGTTAGGG) were ordered from 
Integrated DNA Technologies. The G rich strands were covalently labelled on their 5’ end with 
Cy5 fluorophore. dsDNA was made from annealing Cy5 labelled G rich strands with the 
unlabeled C rich strands.   
Electrophoretic Mobility Shift Assay 
A master mix composed of binding buffer (50 mM HEPES, 50 mM KCl, 1 mM MgCl2, 
0.1 mM EDTA), 1.8 mg/mL BSA, and 3.33 nM Cy5 was prepared. TRF2 protein (0-3600 ng) 
was titrated into 16 L master mix samples and water was added to a final volume of 28 L. 
Samples were left to incubate in the dark for 30 minutes at room temperature. Before loading 
samples, 7.5% polyacrylamide gels (30% APS, 1% TEMED) were pre-run for 30 minutes at 100 
V. Glycerol was added to samples to a final concentration of 10% and samples were loaded into 
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pre-run gels and run in 0.5X TBE buffer at 220 V for 25 minutes in a dark cold room (8°C). Gels 
were viewed using a Typhoon scanner at 650 nm. 
FP Assays 
All experiments were run in triplicates. Background measurements containing binding 
buffer (50 mM HEPES, 50 mM KCl, 1 mM MgCl2, 0.1 mM EDTA) and BSA only were 
subtracted from fluorescence measurements. Fifteen microliter samples were prepared in black 
384-well polypropylene plates using binding buffer, 1.8 mg/mL BSA and varying concentrations 
of Cy5 DNA and TRF2 protein. The TRF2 titration used 5 nM Cy5 DNA and TRF2 
concentrations ranging from 0.05 nM to 1.665 M. Two displacement assays were employed 
using 5 nM Cy5 DNA, 300 nM TRF2, and unlabeled DNA with concentrations ranging from 
0.76 nM to 25 M.  In the first assay, Cy5 DNA and TRF2 were premixed and incubated for 20 
minutes before adding unlabeled DNA. In the second assay, TRF2 and unlabeled DNA were 
premixed and incubated for 20 minutes before adding Cy5 DNA. Plates were spun down and left 
to incubate in the dark for 60 minutes at room temperature. Plates were read using an EnVision 
multilabel plate reader with excitation at 650 nm and emission at 670 nm. 
Z factor Calculation  
To calculate the Z factor, 5 nM Cy5 DNA and 300 nM TRF2 were premixed with 
binding buffer and 1.8 mg/mL BSA and incubated for 20 minutes in black 384-well 
polypropylene plates. Unlabeled DNA was used as a positive control and added to wells to a 
final concentration of 500 M. DMSO was used as a negative control. Plates were spun down 
and left to incubate in the dark for 60 minutes at room temperature. Plates were read using an 
EnVision multilabel plate reader with excitation at 650 nm and emission at 670 nm. 
 
36 
 
III. Results 
An electrophoretic mobility shift assay (EMSA) was used to detect sequence specific 
DNA binding properties of TRF2. This method takes advantage of the concept that free DNA 
will travel farther through a gel than DNA bound to protein because larger complexes experience 
a hindrance in mobility, thus resulting in slower gel migration. Distinct bands visible in the gel 
correspond to protein-DNA complexes providing information on how far the DNA traveled and 
more importantly its extent of binding to a compound of interest. Here the assay was performed 
to ensure proper binding between TRF2 protein and prepared Cy5 labeled DNA. Increasing  
concentrations of TRF2 (0-3600 ng) were titrated into Cy5 DNA and left to incubate before   
 
 
 
Figure 3.3 Mobility Shift Assay for TRF2 Binding Cy5 dsDNA. A shift up in Cy5 DNA 
location is observed at about 1200 ng TRF2. Complex formation is occurring.  
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employing PAGE. While free Cy5 DNA travels farthest down the gel, a major shift upward in 
Cy5 location is observed at about 1200 ng of TRF2, confirming protein-DNA binding (Figure 
3.3).  
Once DNA binding was verified by EMSA, a FP assay was designed using an Envision 
multilabel plate reader for detection. After determining the lowest concentration of Cy5 DNA 
sufficient enough to give a consistent, readable signal, a TRF2 titration experiment was 
performed with 5 nM Cy5 DNA and varying amounts of TRF2 (0.05 nM- 1.665 uM). Here we 
aimed to verify results from the EMSA. The resulting TRF2-DNA binding curve again 
confirmed assay components were behaving properly (Figure 3.4). The Kd of TRF2-DNA 
binding in our assay was calculated to be 182 nM. The literature value Kd was found to be 180 
nM using surface plasma resonance.
47
 An EC80 of 300 nM was used for TRF2 concentrations in 
displacement experiments to ensure that a significant amount of TRF2 remained bound to DNA 
without saturating it. In the displacement assay an excess of unlabeled telomeric DNA was 
titrated into Cy5 DNA-TRF2 complexes to displace Cy5 DNA from protein. Two experiments 
were performed to determine order of addition effects (Figure 3.5). In Experiment #1, Cy5 DNA 
and TRF2 were premixed and incubated before the addition of unlabeled DNA, whereas in 
Experiment #2 TRF2 and unlabeled DNA were premixed and incubated before Cy5 DNA 
addition. As concentrations of unlabeled DNA increase, the FP signal should decrease because 
Cy5 labelled DNA becomes increasingly unbound and as a consequence rotates at a quicker 
speed. In theory, an inhibitor screen should produce similar results as unlabeled TRF2 binding 
DNA. The displacement assay data from Experiment #1 produced an acceptable curve however 
the dynamic range of the assay was narrow.   
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Figure 3.4 TRF2 titration experiment. Cy5 DNA binding to 
TRF2 at varying concentrations 
Figure 3.5 Displacement of Cy5 DNA with unlabeled DNA. Exp. #1 shows Cy5 
DNA and TRF2 premixed before unlabeled DNA addition. Exp. #2 shows TRF2 
and unlabeled DNA premixed before Cy5 DNA addition.  
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To determine if the assay could be used in HTS, a Z factor was calculated. The Z factor is 
a dimensionless statistical score used in HTS analysis to evaluate the quality and efficacy of an 
assay.
45
 It helps decide if the screen has the ability to accurately predict if a compound is active. 
Calculations comprise testing positive and negative controls in replicate, finding the average and 
standard deviation for each control and plugging these values into the equation 1-((3σ- + 3σ+)/(l 
μ- + μ+ l)) . The unlabeled TRF2 DNA was used as the positive control and a random 21 
nucleotide long primer was used as the negative control. Unexpectedly the random primer 
resulted in about 50% binding to TRF2 DNA as compared to the unlabeled positive control 
DNA. The experiment was repeated with DMSO as the negative control (Figure 3.6). An 
excellent Z factor is in the range of 0.5-1 and a marginal assay is between 0 and 0.5. The Z factor  
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Figure 3.6 Z-factor calculation.  Fluorescence measurements for positive 
(unlabeled dsDNA) and negative (DMSO) controls used in Z-factor calculation.   
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was calculated to be 0.12. Based on this calculation, it was concluded that assay efficacy was 
inadequate and further optimization would be required for HTS.  
 
 
IV. Discussion 
There are various limitations to using FP approaches, however the low dynamic range 
proved to be a major reason for the failure of this assay. There are many possible causes for a 
low dynamic range. First, FP requires a large change in molecular volume for maximum change 
in mP value. Our TRF2 protein has molecular weight of 60.26 kDa making it a 120.52 kDa 
homodimer, therefore it is unlikely our TRF2 protein was not large enough to yield a substantial 
mP change. Also, FP measurements increase with molecular weight of the attached compound 
but tend to plateau dependent on the fluorescent lifetime of the fluorophore. This means that the 
fluorescent lifetime of the excited fluorophore must be longer than the rotational correlation time 
of the bound DNA molecule.
42
 This allows the free Cy5 DNA time to randomize its orientation 
during the process of emission for a depolarized effect and lower mP readings. Cy5 has a 
relatively short lifetime of about 1 nanosecond which may not be long enough to allow 
randomization of the labeled DNA. In order to fix this problem it may be advantageous to test a 
fluorophore with a longer lifetime like Flourescien or Alexa Flour 488 both with lifetimes of 
about 4 nanoseconds, or try using a smaller DNA fragment. However, DNA must be long 
enough to ensure attached Cy5 does not affect its binding affinity to TRF2. Additionally 
sometimes DNA will autofluoresce causing significant distortions in the background signal and a 
decrease in the dynamic range of the assay.
46
 An autofluorescence test was performed with the 
unlabeled dsDNA to ensure this was not occurring. Measurements resulted in low FP readings, 
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meaning there was no autofluorescence by DNA. Again, there are various other causes for a low 
dynamic range. This assay will need to be optimized before moving to HTS. Factors to consider 
include fluorophore selection, such as lifetime, stability, and concentration, linker length and 
rigidity, assay component concentrations, and incubation conditions. 
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CHAPTER 4: CLOSING REMARKS 
 
In this thesis two strategies to advance telomere disrupting therapeutics were explored. 
While both had promising findings neither project produced completely ideal results and further 
efforts should be focused on improving experimental methods. The use of antisense 
oligonucleotides to target the hTR subunit of telomerase showed a decrease in enzymatic activity 
suggesting binding was indeed occurring. However, complete inhibition of telomerase was never 
achieved. While optimizing transfection conditions would likely be a valuable endeavor to 
improve experimental results, it is possible that complete inhibition was difficult to achieve 
because hTRas012 is unable to bind preassembled telomerase present in initial cancer cell 
populations. A telomerase complex that is stable with slow turnover will have active telomerase 
that exists throughout multiple hTRas012 dosings. However, telomerase is thought to have a 
half-life of twenty four hours meaning longer transfections should show complete inhibition of 
activity.
48
 Alternatively, the P6.1 loop of telomerase may not be easily accessible to hTRas012 
even prior to holoenzyme assembly. Conserved regions of hTR are predicted to be recognition 
sites for hTR-associated proteins.
9
 These binding proteins may block interactions between 
htRas012 and the hTR P6.1 loop. Fortunately, a variety of oligonucleotides with chemically 
modified backbones have been designed to enhance the therapeutic potential of antisense 
strategies. For example, peptide nucleic acid (PNA) modifications have been shown to be potent 
inhibitors of telomerase with exceptionally high affinity and sequence selectivity forming 
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considerably stable PNA-RNA duplexes in vitro. Therefore it may be favorable to test the 
inhibitory ability of oligonucleotides with PNA backbone modifications.  
Additionally, the FP assay used to observe TRF2 and telomeric DNA interaction 
produced an acceptable binding curve and confirmed components in the assay were behaving 
properly. Unfortunately the low dynamic range of the assay made it impractical for use in high 
throughput screening. Again, optimizing assay conditions may increase the dynamic range of the 
assay, however it may be more desirable to try a different approach. For example, there are many 
alternative methods for studying protein binding interactions including thermal shift assays and 
AlphaScreens.
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Thermal shift assays use thermal-denaturation to evaluate the stability of a target protein 
based on the knowledge that ligands induce conformational changes in proteins, providing 
enhanced stability upon binding. Observations of ligand-dependent changes in the melting 
transition temperatures of ligand-protein complexes relative to the uncomplexed protein are used 
to evaluate ligand binding affinity. In this technique, fluorescent dyes binding hydrophobic 
regions of the target protein are used to monitor protein denaturation. As the protein gets 
denatured in solution, hydrophobic surfaces become increasingly exposed activating fluorescent 
dyes. Using this approach, TRF2 and fluorescent dye are dispensed into microplate wells 
followed by the addition of test compounds to the solution. Plates are then heated and thermal 
melting of TRF2 is monitored by detecting changes in fluorescence. Addition of a stabilizing 
small molecule should shift the midpoint of the melting curves toward a higher temperature. By 
comparing the thermal melting curves of TRF2 in the presence of a small molecule with TRF2 
alone and TRF2 bound to dsDNA, we can determine the extent of small molecule binding to 
assess its inhibiting capability. 
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Alternatively AlphaScreen, a bead based proximity assay, can be used to monitor protein-
ligand binding using a histidine/nickel chelate detection kit. In this technique streptavidin coated 
donor beads bind biotin labeled telomeric DNA, while nickel chelated acceptor beads are used to 
immobilize histidine tagged TRF2. Donor beads contain a photosensitizer phylthalocyanine, 
which upon illumination converts ambient oxygen to an excited and reactive singlet oxygen 
having a 4 μsec half-life. If the acceptor bead is within 200 nm of the donor bead, energy is 
transferred from the singlet oxygen to thioxene derivatives within the acceptor bead producing 
detectable luminescent/fluorescent light.  If the donor bead is not in proximity of the acceptor 
bead then no signal is produced.  When TRF2 and substrate DNA bind, a resulting signal is 
detected. However when a small molecule binds TRF2, interfering with DNA binding, a 
decrease in signal is observed.  
While a FP assay alone could not accurately predict inhibitors of TRF2 there are 
numerous other applications for this technique focusing on protein-ligand interactions, with only 
two presented here. Both of these methods allow for the use of a fully automated, miniaturized 
fluorescence based assay for HTS of small molecule libraries. Similarly, there are countless 
variations to oligonucleotide transfection methods that may be beneficial to consider for this 
study.  Further exploration in these areas will not only advance knowledge of mechanisms 
behind telomere maintenance but assist in the identification and development of future telomere 
targeting therapeutics.  
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